Skip to main content
Zhejiang Medicine Co.,Ltd. logo

Zhejiang Medicine Co.,Ltd. — Investor Relations & Filings

Ticker · 600216 ISIN · CNE0000010J2 LEI · 300300D78ZCY72AGVG73 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,322 across all filing types
Latest filing 2026-05-27 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600216

About Zhejiang Medicine Co.,Ltd.

https://www.zmc.top/en/

Zhejiang Medicine Co., Ltd. is a prominent pharmaceutical and nutritional ingredient manufacturer specializing in the research, development, and large-scale production of vitamins, carotenoids, and anti-infective agents. The company is a leading global supplier of fat-soluble vitamins, including Vitamin E, Vitamin A, and Biotin, as well as Coenzyme Q10 and natural carotenoids such as Lutein and Zeaxanthin. Its pharmaceutical portfolio encompasses active pharmaceutical ingredients and finished dosage forms, with a focus on quinolone antibiotics and glycopeptides like Vancomycin. Serving the human nutrition, animal health, and healthcare sectors, the company maintains rigorous quality standards and leverages advanced biotechnological and chemical synthesis processes to provide high-purity ingredients to international markets.

Recent filings

Filing Released Lang Actions
浙江医药与私募基金合作投资进展公告
Capital/Financing Update Classification · 85% confidence The document is an official announcement by Zhejiang Pharmaceutical Co., Ltd. detailing the progress of its capital investment cooperation with a private equity fund, including the completion of registration, capital contribution details, and overall investment impact. This constitutes an update on the company’s financing activities (i.e., use of capital for investment), fitting the Capital/Financing Update category.
2026-05-27 Chinese
浙江医药与私募基金合作投资公告
Capital/Financing Update Classification · 85% confidence The document is an official announcement by Zhejiang Pharmaceutical Co. regarding its cooperation with a private equity fund, detailing the terms of its capital commitment (RMB6,000 million), investment structure, procedures, risk disclosure, and regulatory approvals. This is not a financial report, dividend notice, share issue, M&A, or management change, but rather a disclosure of a significant financing/investment transaction by the company. It best fits the “Capital/Financing Update” (CAP) category.
2026-05-15 Chinese
浙江医药2025年年度利润分配方案公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an announcement regarding the 2025 annual profit distribution plan of Zhejiang Medicine Co., Ltd. It details the dividend per share, total dividend amount, and related financial figures. The document includes a statement that the plan is subject to approval at the 2025 annual shareholders' meeting. The content focuses on dividend distribution specifics rather than full financial statements or comprehensive annual performance. The document length is 1932 characters, which is relatively short and typical for a dividend announcement. There is no indication that this is a full annual report or an earnings release. The document fits the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and details for shareholders.
2026-04-10 Chinese
浙江医药独立董事2025年度述职报告（吴以扬）
Board/Management Information Classification · 95% confidence The document is a detailed annual performance report of an independent director of Zhejiang Medicine Co., Ltd. It includes the director's background, independence statement, attendance at board and committee meetings, communication with auditors, oversight of financial reporting and internal controls, and evaluation of key governance matters such as related party transactions, auditor appointment, director nominations, executive compensation, and stock incentive plans. The document is titled as an "Independent Director 2025 Annual Performance Report" and is signed and dated in 2026. It is not a general annual report, audit report, or financial statement, but a governance-related report focusing on the independent director's duties and oversight activities. This fits best under the category of Board/Management Information (MANG), which covers announcements or reports related to company board members and senior management activities. The document length is under 5,000 characters, but it is a substantive report, not a mere announcement of a report publication. Therefore, the classification is MANG with high confidence.
2026-04-10 Chinese
浙江医药独立董事2025年度述职报告（裘益政）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2025 Annual Work Report" for Zhejiang Medicine Co., Ltd. It is a detailed report by an independent director about their duties, attendance, supervision activities, and opinions on company governance and financial matters during the year 2025. The content focuses on the director's role, attendance at board meetings, audit committee activities, communication with auditors, and evaluation of financial reports and internal controls. It does not contain financial statements or quarterly/annual financial results but is a narrative report on the director's activities and oversight. This type of document fits best under Board/Management Information (MANG), as it relates to management and board-level reporting on governance and oversight activities rather than a financial report or announcement. The document length is 3825 characters, which is substantial for a report but not a full financial report. Therefore, the classification is MANG with high confidence.
2026-04-10 Chinese
浙江医药2025年度非经营性资金占用及其他关联资金往来情况的专项审计说明
Audit Report / Information Classification · 97% confidence The document is a special audit report (“专项审计说明”) prepared by the registered accounting firm, containing auditor and management responsibilities, audit scope, conclusions, and detailed tables of non-operating funds occupancy and related party transactions. It is a standalone audit report on a specific matter, separate from the full annual report. This clearly matches the “Audit Report / Information (AR)” category. FY 2025
2026-04-10 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.